|
|
|
Stents
|
Stents are commonly used within catheterization procedures to reduce the incidence of artery or vessel reclosure. Examples of stents reviewed within Cath Lab Digest are coronary, peripheral, drug eluting, bare metal, and bioabsorbable stents. Click on one of our stent links for more information |
|
DES Controversy: Are We Asking the Wrong Questions?
Abstract. Studies comparing stents and optimizing post-procedural anti-platelet regimens abound. We should re-focus on optimizing stent deployment and maintaining a registry of how we are using and deploying drug-eluting stents.
|
Clinical and Industry News
By simultaneously comparing patients in four treatment groups defined by stent type and clopidogrel use, we found that patients with a drug-eluting stent receiving clopidogrel six and twelve months after their initial procedure have significantly lower rates of death and death or MI (myocardial infarction) compared with patients with a drug-eluting stent not receiving this medication,? s extensive Endeavor® drug-eluting stent clinical trial program at a special U.S. Food and Drug ...
|
The TAXUS ATLAS Trial: Workhorse lesions and direct stenting with the Liberté paclitaxel-eluting stent
How do the TAXUS Express2 and Liberté stent platforms differ? The TAXUS Liberté stent was designed specifically for drug delivery. It has a uniform cell architecture and a crossing profile smaller than the crossing profile of the Express2 platform.
|
News from the Transcatheter Cardiovascular Therapeutics Meeting (TCT)
Held in Washington, D.C., October 22?27, 2006
|
The Sideguard? Ostium Protection Device: The next generation in bifurcation stenting
Reviewed by Donald S. Baim, MD, Director, Center for Integration of Medicine and Innovative Technology, Brigham and Women?s Hospital; Professor of Medicine, Harvard Medical School; Boston, Massachusetts. *This article is based in part on interviews with Dr. Antonio Colombo, Dr. Donald Baim, and Dr. Campbell Rogers.
|
Anticipating the Era of Drug-Eluting Stents
Health care providers in the U.S. caring for patients with cardiovascular disease are eagerly awaiting approval of drug-eluting stents for the prevention and treatment of restenosis. Recent experimental breakthroughs and clinical trial progress involving this revolutionary technology promise a great future for the less invasive care of patients with coronary artery disease. This article will summarize the basic components required to produce an anti-restenotic drug eluting stent, and describe the programs and clinical results with the furthest developed devices in this field.
|
The Smaller Contenders for the DES Market
The progress of the major stent manufactures for drug-eluting stent (DES) FDA approval and marketing is well-documented. Boston Scientific Corporation and Cordis Corporation are now battling it out for dominance of this multi-billion dollar industry. Guidant is soon to become a division of Johnson & Johnson or Boston Scientific, and Medtronic is working diligently to receive FDA approval so they can also enter this lucrative market. However, few know that a growing number of smaller companies have also developed DES products.
|
The STENT Registry: A Real-World Look at Sirolimus- and Paclitaxel-Eluting Stents
Cath Lab Digest talks with registry founder Charles Simonton, MD, Carolinas Medical Center, Charlotte, North Carolina
|
The Perfect Fit: Getting the Most Out of Your Coronary Stent
Post-dilatation Early-generation balloon-expandable stents were delivered with compliant balloons and required post-dilatation with noncompliant balloons at higher pressure to optimize stent deployment. These include: 1. IVUS for assessment of the lesion pre-stenting and verification of apposition and expansion post-stenting; 2. Pre-dilatation balloon catheters, the Cutting Balloon Device and rotational atherectomy for lesion preparation to optimize stent deployment; and 3. Noncompliant post...
|
Research Update: The following original research abstracts are from the November, December (2001) and January and February (2002) issues of the Journal of Invasive Cardiology
728 Self-Expanding Stents for Carotid Interventions: Comparison of Nitinol Versus Stainless-Steel Stents Debabrata Mukherjee, MD, *Vidyasagar Kalahasti, MD, *Marco Roffi, MD, *Deepak L. Bhatt, MD, *Samir R. Kapadia, MD, *Christopher Bajzer, MD, *Joel Reginelli, MD, *Khaled M. Ziada, MD, *Kathy Hughes, RN, *Jay S. Yadav, MD ABSTRACT: Background. 799 Triple Vessel Stenting for Triple Vessel Coronary Disease Beatriz Villegas, MD, Marie-Claude Morice, MD, Salvador Hernandez, MD, Rémi Choussat, ...
|
|
|
|
|
|
|
|
On Demand Medical Education
|
|
|
|
|
